141 related articles for article (PubMed ID: 36430230)
21. Idasanutlin and navitoclax induce synergistic apoptotic cell death in T-cell acute lymphoblastic leukemia.
Johansson KB; Zimmerman MS; Dmytrenko IV; Gao F; Link DC
Leukemia; 2023 Dec; 37(12):2356-2366. PubMed ID: 37838759
[TBL] [Abstract][Full Text] [Related]
22. Interactions of pro-apoptotic BH3 proteins with anti-apoptotic Bcl-2 family proteins measured in live MCF-7 cells using FLIM FRET.
Liu Q; Leber B; Andrews DW
Cell Cycle; 2012 Oct; 11(19):3536-42. PubMed ID: 22895112
[TBL] [Abstract][Full Text] [Related]
23. Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination.
Lew TE; Seymour JF
J Hematol Oncol; 2022 Jun; 15(1):75. PubMed ID: 35659041
[TBL] [Abstract][Full Text] [Related]
24. Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells.
Abed MN; Abdullah MI; Richardson A
J Ovarian Res; 2016 Apr; 9():25. PubMed ID: 27080533
[TBL] [Abstract][Full Text] [Related]
25. Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199).
Phillips DC; Xiao Y; Lam LT; Litvinovich E; Roberts-Rapp L; Souers AJ; Leverson JD
Blood Cancer J; 2015 Nov; 5(11):e368. PubMed ID: 26565405
[TBL] [Abstract][Full Text] [Related]
26. BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAF
Hartman ML; Gajos-Michniewicz A; Talaj JA; Mielczarek-Lewandowska A; Czyz M
Cancer Lett; 2021 Feb; 499():122-136. PubMed ID: 33259900
[TBL] [Abstract][Full Text] [Related]
27. Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737.
Oakes SR; Vaillant F; Lim E; Lee L; Breslin K; Feleppa F; Deb S; Ritchie ME; Takano E; Ward T; Fox SB; Generali D; Smyth GK; Strasser A; Huang DC; Visvader JE; Lindeman GJ
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2766-71. PubMed ID: 21768359
[TBL] [Abstract][Full Text] [Related]
28. γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells.
Séveno C; Loussouarn D; Bréchet S; Campone M; Juin P; Barillé-Nion S
Breast Cancer Res; 2012 Jun; 14(3):R96. PubMed ID: 22703841
[TBL] [Abstract][Full Text] [Related]
29. MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.
Konopleva M; Milella M; Ruvolo P; Watts JC; Ricciardi MR; Korchin B; McQueen T; Bornmann W; Tsao T; Bergamo P; Mak DH; Chen W; McCubrey J; Tafuri A; Andreeff M
Leukemia; 2012 Apr; 26(4):778-87. PubMed ID: 22064351
[TBL] [Abstract][Full Text] [Related]
30. Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells.
Mérino D; Khaw SL; Glaser SP; Anderson DJ; Belmont LD; Wong C; Yue P; Robati M; Phipson B; Fairlie WD; Lee EF; Campbell KJ; Vandenberg CJ; Cory S; Roberts AW; Ludlam MJ; Huang DC; Bouillet P
Blood; 2012 Jun; 119(24):5807-16. PubMed ID: 22538851
[TBL] [Abstract][Full Text] [Related]
31. Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B.
Rooswinkel RW; van de Kooij B; Verheij M; Borst J
Cell Death Dis; 2012 Aug; 3(8):e366. PubMed ID: 22875003
[TBL] [Abstract][Full Text] [Related]
32. Synergistic cooperation between ABT-263 and MEK1/2 inhibitor: effect on apoptosis and proliferation of acute myeloid leukemia cells.
Airiau K; Prouzet-Mauléon V; Rousseau B; Pigneux A; Jeanneteau M; Giraudon M; Allou K; Dubus P; Belloc F; Mahon FX
Oncotarget; 2016 Jan; 7(1):845-59. PubMed ID: 26625317
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of BH3 mimetics as a combination therapy with irradiation in head and neck squamous cell carcinoma.
Korelin K; Oostveen M; Wahbi W; Ianevski F; Cavalcante B; Turunen L; Belevich I; Al-Samadi A; Salo T
Biomed Pharmacother; 2024 May; 175():116719. PubMed ID: 38749173
[TBL] [Abstract][Full Text] [Related]
34. Synergistic cytotoxicity of Bcl-xL inhibitor, gossypol and chemotherapeutic agents in non-Hodgkin's lymphoma cells.
Li ZM; Jiang WQ; Zhu ZY; Zhu XF; Zhou JM; Liu ZC; Yang DJ; Guang ZZ
Cancer Biol Ther; 2008 Jan; 7(1):51-60. PubMed ID: 17938578
[TBL] [Abstract][Full Text] [Related]
35. Binding affinity of pro-apoptotic BH3 peptides for the anti-apoptotic Mcl-1 and A1 proteins: Molecular dynamics simulations of Mcl-1 and A1 in complex with six different BH3 peptides.
Modi V; Sankararamakrishnan R
J Mol Graph Model; 2017 May; 73():115-128. PubMed ID: 28279820
[TBL] [Abstract][Full Text] [Related]
36. Bim directly antagonizes Bcl-xl in doxorubicin-induced prostate cancer cell apoptosis independently of p53.
Yang MC; Lin RW; Huang SB; Huang SY; Chen WJ; Wang S; Hong YR; Wang C
Cell Cycle; 2016; 15(3):394-402. PubMed ID: 26694174
[TBL] [Abstract][Full Text] [Related]
37. BH3 mimetics: status of the field and new developments.
Billard C
Mol Cancer Ther; 2013 Sep; 12(9):1691-700. PubMed ID: 23974697
[TBL] [Abstract][Full Text] [Related]
38. BH3 mimetics inhibit growth of chondrosarcoma--a novel targeted-therapy for candidate models.
Morii T; Ohtsuka K; Ohnishi H; Mochizuki K; Yoshiyama A; Aoyagi T; Hornicek FJ; Ichimura S
Anticancer Res; 2014 Nov; 34(11):6423-30. PubMed ID: 25368242
[TBL] [Abstract][Full Text] [Related]
39. Navitoclax (ABT-263) accelerates apoptosis during drug-induced mitotic arrest by antagonizing Bcl-xL.
Shi J; Zhou Y; Huang HC; Mitchison TJ
Cancer Res; 2011 Jul; 71(13):4518-26. PubMed ID: 21546570
[TBL] [Abstract][Full Text] [Related]
40. The first MCL-1-selective BH3 mimetics have therapeutic potential for chronic lymphocytic leukemia.
Besbes S; Pocard M; Mirshahi M; Billard C
Crit Rev Oncol Hematol; 2016 Apr; 100():32-6. PubMed ID: 26899021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]